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h is largely recovered posttreatment
received peginterferon/ribavirin for
nly partial recovery is seen in children
eeks.Objectives: The aim of the study was to describe the 5-year follow-up of
children who received peginterferon and ribavirin in a global, open-label study.
Methods: A 5-year follow-up study of 107 children and adolescents ages 3 to
17 years with chronic hepatitis C virus infection who received peginterferon
and ribavirin for 24 or 48 weeks. No drugs were administered during follow-up.
Results: Ninety-four patients were enrolled in the long-term follow-up portion
of the study; the median duration of follow-up was 287 weeks (range, 73–339).
Of 63 patients with sustained virologic response who were enrolled, 54
completed 5 years of follow-up; none had relapse in the 5-year follow-up
period. Significant decreases in height z scores were observed during
treatment. The effect of treatment on height z score was larger in patients
treated for 48 weeks compared with those treated for 24 weeks (mean change
from baseline to the end of treatment was 0.13 [P< 0.001] and 0.44
[P< 0.001] in the 24- and 48-week treatment groups, respectively). Among
patients treated for 24 weeks, full recovery of height z scores to baseline was
observed by 1 year of follow-up, whereas only partial recovery was observed
during 5 years of follow-up in patients treated for 48 weeks (mean change from
baseline to the final follow-up visit was0.16 (P¼NS) and0.32 (P< 0.05)
in the 24- and 48-week treatment groups, respectively). Similar patterns were
observed for weight and body mass index z scores.
Conclusions: Impairment of growth should be considered when assessing
the risk-benefit profile of peginterferon/ribavirin therapy in children
with hepatitis C virus infection. In deciding to treat children with chronic
hepatitis C virus, considerations should include both deferring treatment in
patients during optimal growth periods, and the possibility that interferon-
free regimens may be available to children in the next 5 to 10 years.
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Haber et al JPGN  Volume 64, Number 1, January 2017Furthermore, children with HCV infection have a communicable
disease that can result in exclusion from activities such as sports; it
is also preferable to treat HCV infection before a person becomes
sexually active or becomes pregnant.
Treatment options for children with hepatitis C are limited.
Direct-acting antiviral agents have dramatically altered the HCV
treatment landscape in adult patients, but these agents are not yet
approved for use in children. Therefore, peginterferon and ribavirin
remains the standard of care for children with HCV infection
involving a lengthy treatment regimen associated with unfavorable
tolerability, and without guaranteed viral eradication (2–4). Rates
of sustained virologic response (SVR) are approximately 58% in
children with HCV treated with peginterferon and ribavirin (3).
The risks of progressive liver disease and the challenging
treatment regimen must be weighed against the opportunity for viral
eradication when considering treatment of children with HCV
infection. One of the major risks regarding treatment of children
with interferon-based therapy is the potential effect on growth and
development. Reduced growth rates in children have been reported
during interferon-based therapy, and it remains unclear to what
extent growth is recoverable after completion of treatment (2,5,6).
Wirth and colleagues studied the treatment of HCV infection in 107
children receiving peginterferon and ribavirin in a global, open-
label study (2). Weight loss was common but was largely recovered
during the 24-week follow-up period; mean weight percentile was
56.6 at baseline and 53.4 at end of follow-up. Linear growth was
also inhibited during treatment and remained below the median for
the US population at the end of 24 weeks of follow-up (mean height
percentiles were 50.9 at baseline and 44.25 at the end of follow-up).
Similarly, Jonas et al (6) reported declining weight, height, and
body mass index (BMI) scores in children receiving peginterferon
with or without ribavirin in the Pediatric Study of Hepatitis
C (PEDS-C). In the present study, weight-for-age and BMI-for-
age scores returned to baseline values after completion of treatment;
however, height-for-age scores had not recovered to baseline
96 weeks after treatment completion (6). Here, we report on the
5-year follow-up of the children and adolescents enrolled in
the study by Wirth et al (2). Children who attained SVR were
followed for durability of response, and the long-term implications
of interferon-based therapy, particularly with regard to height and
weight development, were also studied.
METHODS
This is a long-term follow-up (LTFU) study of children with
HCV infection enrolled in a global, multicenter, open-label study to
evaluate the efficacy, safety, and pharmacokinetics of peginterferon
alfa-2b and ribavirin (NCT00104052; protocol P02538). Full details
of the study have been published previously (2). Informed consent
was obtained from all patients before enrollment in the initial
treatment study and again when patients entered the follow-up
protocol. These studies were conducted in accordance with
the provisions of the Declaration of Helsinki, the International
Conference on Harmonization guidelines, and other regulations
governing clinical study conduct. The protocols were approved by
an independent ethics committee or institutional review board at
each participating site.
Patients and Initial Treatment
Children ages 3 to 17 years with previously untreated
HCV infection were eligible for enrollment in the original treatment
study. Children with decompensated liver disease, human immuno-
deficiency virus or hepatitis B virus coinfection, or other significant
comorbidities were excluded from the original treatment protocol. Copyright © ESPGHAN and NA
90All patients received peginterferon alfa-2b (60 mg/m /week,
based on approximate equivalence to the adult-approved dose of
1.5 mg/kg/week) and ribavirin (15 mg/kg/day, based on previously
established effective dosing (7)). Doses of ribavirin did not exceed
1200 mg/day; therefore, children with body weight >90 kg were
also excluded. Patients with HCV G1, G2, or G3, and baseline viral
load 600,000 IU/mL were treated for 48 weeks, and those with
G2 or G3 infection and low baseline viral load <600,000 IU/mL
were treated for 24 weeks. Patients with <2 log10 decline in HCV
RNA at week 12 or detectable HCV RNA at week 24 were
discontinued from the study based on futility. The primary end
point in the original treatment protocol was SVR (defined as
undetectable HCV RNA at follow-up week 24). Secondary end
points were on-treatment virologic response and safety assessments,
including measurements of weight and height.
Long-Term Follow-up
Patients who received 1 dose of medication during the
initial treatment study and completed 24 weeks of posttreatment
follow-up were eligible for enrollment in the LTFU portion of the
study. No drugs were administered during the LTFU portion.
Patients who underwent re-treatment for HCV infection after
completing the initial treatment protocol were excluded from the
follow-up study.
Initial follow-up visits were scheduled approximately 1 year
after the follow-up week 24 visit in the original study. Patients who
attained SVR had 1 visit per year for up to 5 years, whereas patients
with detectable HCV RNA at follow-up week 24 (no SVR) had
visits every 6 months during follow-up. Patients who were not able
to enter the study at the year 1 visit were able to enter the study at
later time points.
The primary end point of this follow-up study was durability
of SVR. HCV RNA levels were measured yearly for assessment
of durability of SVR and every 6 months in non-SVR patients. A
patient was classified as a sustained responder at a given time point
if HCV RNAwas below the lower limit of quantitation (LLQ) at that
time point. Plasma HCV RNA levels were measured at a central
laboratory using the HCV RNA COBAS Taqman 2.0 assay (Roche,
Indianapolis, IN, LLQ¼ 25 IU/mL). Confirmatory testing was
performed in patients with initial SVR and subsequent detectable
HCV RNA during follow-up. If the initial positive value was
confirmed, then HCV genotype was tested at the central laboratory
to determine whether the patient had relapsed or had been reinfected
with a different genotype.
Safety assessments, along with physical examinations
(including a gastrointestinal/liver examination), vital signs, body
weight, height, and laboratory safety tests (serum chemistry, hema-
tology, thyroid-stimulating hormone [TSH]) were performed at
each visit. Only serious adverse events (SAEs) that occurred after
the patient had completed the 24-week posttreatment follow-up
were reported. All adverse events relating to progression of liver
disease were reported as SAEs.
Height was measured using the same instrument at each
clinic visit (stadiometer, if available), or measuring tape affixed to
the wall; weight was measured using the same scales at each clinic
visit. Growth analyses were adjusted for age (height, weight, BMI
percentiles), and z scores were derived for each patient using an
SAS macro provided by the Centers for Disease Control and
Prevention. Each z score represents data as a standard deviation
(SD) from the population norm within each age group. For example,
a height z score of 1 indicates a value 1 SD below the normative
population for height, whereas an z score of þ1 is 1 SD above the
normative population. Z scores were summarized using descriptiveSPGHAN. All rights reserved.
www.jpgn.org
JPGN  Volume 64, Number 1, January 2017 Long-Term Follow-Up of Children Treated for HCV Infectionstatistics as changes from baseline at each time point during
follow-up, where baseline was taken as the start of the treatment
period. An ad-hoc statistical test of the z scores was performed
by parameter and time point to test null hypothesis of 0; P values
are 2-sided, based on the t distribution, and unadjusted for multiple
comparisons.
RESULTS
Patient Disposition and Baseline Demographics
In total, 94 of the 107 patients who participated in the original
treatment study across 20 sites in 7 countries were enrolled in this
LTFU analysis (Table 1). The study disposition reflects that 80
patients completed the study and 14 discontinued before completing
5 years of follow-up (Supplementary Fig. 1, Supplemental Digital
Content, http://links.lww.com/MPG/A664). Of the 14 patients who
discontinued, 1 was due to noncompliance with the protocol, 6 were
due to withdrawal of consent, 6 were lost to follow-up, and 1 was for
administrative reasons. The median duration of follow-up for these
94 patients was 287 weeks (range, 73–339).
Of the 94 patients followed during LTFU, 48% were boys,
52% were 3 to 10 years of age at enrolment, and 48% were 11 to
17 years of age. None of the patients had a medical history of
thyroid disorders or insulin-dependent diabetes. Approximately half
of the enrolled patients (46/94, 49%) were treated for24 weeks, of
which 26 (57%) had SVR and 20 (43%) were nonresponders. The
remaining 48 patients (51%) were treated for 48 weeks, of which
37 (77%) had SVR and 11 (23%) were nonresponders. One patient Copyright © ESPGHAN and NA









Male 18 27 45
Female 31 18 49
Race
White 46 35 84
Black 1 0 1
Asian 1 5 6
Multiracial 1 2 3
Ethnicity
Hispanic/Latino 9 4 13
Non-Hispanic/Latino 40 41 81
Genotype
G1 33 28 61
G2 6 9 15
G3 8 6 14
G4 2 2 4
Baseline viral load
<600,000 IU/mL 28 24 52
>600,000 IU/mL 19 19 38
Missing 2 2 4
Previous treatment duration
24 weeks 20 26 46
48 weeks 29 19 48
Previous treatment outcome
SVR 32 31 63
Nonresponse 17 14 31
SVR ¼ sustained virologic response.
www.jpgn.orgin the original treatment study discontinued after 18 weeks
of treatment.
Durability of Sustained Virologic Response
A total of 63 patients with SVR from the treatment portion of
the protocol were enrolled, 54 of whom completed 5 years of
follow-up (Supplementary Fig. 2, Supplemental Digital Content,
http://links.lww.com/MPG/A665). All 54 patients had valid HCV-
RNA results at year 5 and none relapsed during the 5-year follow-up
period (in all patients HCV RNA was below the LLQ of 25 IU/mL
throughout follow-up).
Two patients had HCV-RNA levels that were detectable but
below the LLQ during the LTFU. One of these patients had
detectable/unquantifiable HCV RNA at the year 3 time point
(confirmed on retesting of the same sample), and also had a similar
result on a sample taken approximately 6 months later. The year
4 sample was not available for analysis; however, testing of the year
5 sample from this patient revealed undetectable HCV RNA. The
second patient with unquantifiable HCV RNA during follow-up had
detectable/unquantifiable HCV RNA at year 5 and was not mon-
itored further. Genotype data from samples obtained during follow-
up are not available for either patient.
Of the 9 patients with SVR who did not complete 5 years of
follow-up, 7 dropped out prematurely (none of whom had relapsed
before discontinuation) and 2 patients completed 5 years of follow-
up with sustained response through LTFU year 4, but the year 5
sample was not available for analysis.
There were 31 previous nonresponders with quantifiable
HCV RNA at the end of the original treatment protocol who
entered the follow-up study. None had HCV RNA <LLQ during
the follow-up period.
Safety
A total of 5 SAEs were reported in 3 patients during LTFU,
none of which were considered to be related to peginterferon/
ribavirin therapy. Two patients had appendicitis, and there were
3 reports of talipes (growth delay of congenital clubfoot) in
1 patient. There were no deaths, no discontinuations due to an
adverse event, and no discontinuations due to chronic liver disease.
Height
Significant decreases in height z scores were observed during
treatment. The effect of treatment on mean change from baseline in
height z score was larger in patients treated for 48 weeks compared
with those treated for 24 weeks. Patients treated for 24 weeks had
a mean change from baseline in height z score of0.13 (SD¼ 0.20,
P< 0.001) at the end of treatment, and 0.16 (SD¼ 0.62, P¼NS)
at the end of follow-up. Among patients treated for 24 weeks, mean
height z scores had returned to baseline levels by year 1 of follow-up
and remained stable thereafter. In contrast, patients treated for
48 weeks had a mean change from baseline in height z score
of 0.44 (SD¼ 0.34, P< 0.001) at the end of treatment and
0.32 (SD¼ 0.80, P< 0.05) at the end of follow-up. Mean height
z scores declined during the treatment period, partially recovered
by year 1 of follow-up, but then showed no further increase with
continued follow-up (Table 2, Fig. 1).
The mean change in height percentile from baseline to the
final follow-up visit was 3.0 percentiles and 8.9 percentiles for
the 24- and 48-week treatment groups, respectively. Supplementary
Table 1 (Supplemental Digital Content, http://links.lww.com/MPG/
A666) presents data according to sex and age subgroup. Overall,SPGHAN. All rights reserved.
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Haber et al JPGN  Volume 64, Number 1, January 2017patient numbers are small, and effect on mean height percentile
appears to be primarily related to treatment duration (24 vs
48 weeks), regardless of age or sex.
Overall, 30 of 94 (31.9%) of patients had a decrease in height
of >15 percentiles between baseline in the original treatment
protocol and the final follow-up visit. The proportion of patients
with a reduction of >15 percentiles was similar in boys and girls
(31% vs 33%), but appeared higher in the 48-week treatment
group compared with the 24-week treatment group. In total,
12 of 30 (40%) girls and 7 of 18 (39%) boys who received 48 weeks
of treatment had a >15 percentile-point decrease in height from
baseline to the end of follow-up, whereas 4 of 19 (21%) girls and
7 of 27 (26%) boys treated for 24 weeks had a >15 percentile-point
decrease in height from baseline to the end of follow-up.
Weight and Body Mass Index
Weight z scores decreased during treatment, with a mean
change from baseline of0.50 and0.75 at the end of treatment in
patients treated for 24 and 48 weeks, respectively. There was then a
marked rebound during year 1 of follow-up, with a mean change
from baseline in weight z scores of þ0.03 and 0.16 at the end of
year 1 in patients treated for 24 and 48 weeks, respectively, and
stabilizing thereafter for the remainder of follow-up (mean change
from baseline in weight z scores at the end of LTFU were0.08 and
0.21, respectively; Table 3, Fig. 1). Similar profiles were also seen
with mean change from baseline in BMI z scores during treatment
and follow-up (Table 3, Fig. 1).
Thyroid Dysfunction and Insulin-Dependent
Diabetes
Abnormal TSH levels were measured in 22 of 94 (23%)
patients during treatment or follow-up. During the treatment phase,
20 (21%) of the patients had abnormal TSH values, most of which
were above the normal range. During follow-up, 4 (4%) of the
patients had an abnormal TSH level: 2 had abnormal TSH levels
during treatment and during follow-up, 1 had an abnormal TSH
level during year 1 of follow-up with normal values throughout the
treatment phase, and 1 had an abnormal TSH level at the final year
5 follow-up visit.
Three patients received levothyroxine during the treatment
phase and 1 patient was treated during the LTFU portion: 3 had
subsequent normal TSH values throughout LTFU; 1 had normal
TSH values at LTFU years 1 and 2 and an elevated TSH level at
LTFU year 3. No patient developed insulin-dependent diabetes.
DISCUSSION
Data from the present analysis further inform the debate
regarding treatment of children with HCV with interferon-based Copyright © ESPGHAN and NA







for 24 wk (n¼ 46)
0.13 (0.20) 0.12 (0.29) 0.04 (0.43)
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92antiviral therapy. In our cohort, SVR was durable with no late
relapse and, therefore, consistent with previous reports of LTFU in
children (5,8) and with observations in adult patients (9–11). SVR
can be considered to be indicative of viral eradication.
The present study represents a long-duration follow-up of
children treated for HCV with interferon-based antiviral therapy.
Importantly, a relatively low rate of thyroid disease was observed
following treatment, with abnormal TSH levels reported in only 4%
of patients during LTFU. We, however, found that treatment with
peginterferon and ribavirin was associated with impaired growth.
During the treatment portion of the protocol, height, weight, and
BMI z scores declined compared with a normative population
by 0.13, 0.50, and 0.60, respectively, for those treated for
<48 weeks and by0.44,0.73, and0.71, respectively, for those
treated for 48 weeks. In children treated for <48 weeks, a full
recovery to pretreatment z score was observed for height, weight,
and BMI by 1 year after the end of treatment. For children treated
for 48 weeks, height, weight, and BMI demonstrated some
recovery toward pretreatment z score at 2 years of follow-up;
however, full recovery for height, weight, or BMI was still not
achieved at follow-up year 5.
In this analysis, height was measured using the same instru-
ment at each clinic visit (stadiometer, if available), or measuring
tape affixed to the wall, and weight was measured using the same
scales at each clinic visit. Although Tanner staging was performed
during this study, the effect of treatment duration on height as it
relates to sexual maturation could not be evaluated because of small
sample sizes when data were split by Tanner stage, sex, and duration
of treatment. We also do not have a full assessment of parental
height as it relates to growth during the study. Parental height
data for both parents are only available for 14 of 30 patients with a
>15 percentile decrease in height, of which 10 patients had an
estimated final height within the normal range.
A number of other studies have reported a similar effect of
interferon-based antiviral therapy on growth in children (2,4,7).
A meta-analysis of 8 studies assessing interferon-based antiviral
therapy in children with HCV infection noted small growth inhi-
bition, although data were generally considered inconsistent and
unsuitable for meta-analytical methods (3). Overall studies with
native interferon tend to report a reversible effect on growth
inhibition, with a decrease in height or weight percentile during
treatment that is matched by an increase in percentile during the
24-week follow-up, even when treatment is continued for up to
48 weeks (7). In contrast, studies with pegylated interferon indicate
a more profound inhibition of growth during treatment that is not
fully recovered during the 24-week follow-up period (2,6).
Fewer investigations have considered the long-term
consequences of treatment-related growth impairment beyond
the standard 24-week follow-up period that is typically used in
the treatment of HCV infection. Follow-up of children enrolled inSPGHAN. All rights reserved.
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FIGURE 1. Change from baseline in z scores for weight, height, and BMI. BMI ¼ body mass index, BMIZ ¼ BMI-for-age z score, EOF ¼ end of
follow-up, EOT ¼ end of treatment, HAZ ¼ height-for-age z score, PEG INF ¼ pegylated interferon, WAZ ¼ weight-for-age z score.
JPGN  Volume 64, Number 1, January 2017 Long-Term Follow-Up of Children Treated for HCV InfectionPEDS-C showed significant growth inhibition in children treated
with peginterferon and ribavirin when followed for up to 2 years,
particularly among children treated for at least 48 weeks (6).
Among a small subgroup of patients followed-up for up to 6 years
after treatment, no long-term effects on height were identified
that could be attributed to HCV treatment (8). Among 28 patients
who received treatment for 48 to 52 weeks, 4 (14%) had a
>15-percentile point reduction in height at 2 years after treatment;
at the end of LTFU, only 2 (7%) remained >15-percentile points
below baseline, one of whom had precocious puberty and the other
genetic short stature based on height of family members (8). In
contrast to the present study which enrolled 88% (94/107) of
patients from the original treatment study, LTFU of the PEDS-C Copyright © ESPGHAN and NA
TABLE 3. Mean change from baseline in weight and body mass index z
EOT 24-wk follow-up LTFU
Weight
Peginterferon/ribavirin for 24 wk 0.50 (0.26) 0.08 (0.27) þ0.03
Peginterferon/ribavirin for 48 wk 0.75 (0.39) 0.22 (0.34) 0.16
BMI
Peginterferon/ribavirin for 24 wk 0.60 (0.41) 0.04 (0.34) þ0.04
Peginterferon/ribavirin for 48 wk 0.71 (0.61) 0.02 (0.45) 0.04
BMI¼ body mass index; EOT¼ end of treatment; LTFU¼ long-term follow
P< 0.001.
P< 0.05.
www.jpgn.orgcohort included only a limited subset (33%, 38/114) of patients from
the original treatment study (8). Similarly, Kelly et al (5) reported
growth inhibition in children treated with native interferon and
ribavirin, with partial recovery in height percentile during LTFU.
Among 97 children treated with interferon alfa and ribavirin (70%
of whom were followed for 5 years), mean height percentiles were
48 at pretreatment baseline, 37 at end of treatment week 24, 40 at the
24-week posttreatment follow-up, and 44 at the final LTFU visit.
Median duration of follow-up was 284 weeks (5). Furthermore,
21 of the patients followed by Kelly et al had a>15 percentile-point
decrease in height at their final visit during LTFU and 14 of these
21 agreed to continued monitoring (9 patients had complete data;
5 patients could not be evaluated due to missing parental heights).SPGHAN. All rights reserved.
scores, adjusted for baseline age and sex
year 1 LTFU year 2 LTFU year 3 LTFU year 4 LTFU year 5
(0.41) þ0.04 (0.52) 0.06 (0.53) þ0.04 (0.56) 0.08 (0.68)
(0.55) 0.17 (0.58) 0.19 (0.59) 0.22 (0.73) 0.21 (0.71)
(0.48) 0.05 (0.58) 0.14 (0.53) 0.04 (0.66) 0.07 (0.73)
(0.56) 0.13 (0.59) 0.14 (0.58) 0.17 (0.70) 0.14 (0.62)
-up.
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up and all 3 continued to show height deficits>15 percentile points.
The remaining 6 patients were older than 20 years at final follow-
up; only 1 patient had greater than the predicted midparental height,
but all 6 patients had heights within 2 SDs of the predicted height.
Thus, among these 14 children who had a >15 percentile-point
decrease in height during treatment with peginterferon and riba-
virin, growth impairment was not recovered when assessed as
young adults. Overall, our data are consistent with those reported
by Jonas et al and Kelly et al, suggesting that treatment with
peginterferon and ribavirin is associated with growth inhibition.
Our data, for the first time, reveal that growth inhibition during
treatment is not recovered, even when children are followed for up
to 5 years after completing therapy.
In children ages 3 to 17 years, peginterferon alfa-2b, in
combination with ribavirin, is approved for the treatment of
chronic hepatitis C at a dose of 60 mg/m2/week (12). Peginter-
feron alfa-2a is approved for children older than 5 years at a dose
of 180 mg/1.73 m2 body surface area. The prescribing infor-
mation for both peginterferon alfa-2a and -2b suggest a treatment
duration of 24 weeks in patients with G2/3 infection and 48
weeks for patients with other genotypes, and also note the
potential for weight loss and growth impairment during treat-
ment. Based on futility, patients with a <2 log10 decline in HCV
RNA at treatment week 12 or detectable HCV RNA at treatment
week 24 should be withdrawn from treatment (12). Based on the
findings of this analysis, the following warning has been added to
the peginterferon alfa-2b label: ‘‘Weight and height gain of
pediatric patients lags behind that predicted by normative popu-
lation data for the entire length of treatment. Severely inhibited
growth velocity was observed in 70% of the patients while on
treatment. Of these patients, 20% had continued inhibited growth
velocity after 6 months of follow-up’’ (12). The most recent
treatment guidelines from the American Association for the
Study of Liver Diseases (AASLD) do not include recommen-
dations for treatment of children with HCV infection (13);
however, older guidelines note the approval of peginterferon
alfa-2b and ribavirin in this indication (14). Interferon-free
regimens using direct-acting antiviral agents, such as sofosbuvir
and ledipasvir/sofosbuvir, are currently being investigated in
children younger than 18 years (15), and future studies are
planned for elbasvir/grazoprevir.
In conclusion, SVR was observed to be durable in the present
study. All patients with SVR during the treatment phase who
enrolled in the LTFU continued to be sustained responders. Among
children treated for <48 weeks, height, weight, and BMI demon-
strated full recovery to baseline values within 1 year of end of
treatment. Only partial recovery was, however, seen in patients
treated for 48 weeks. These data suggest that impairment of
growth should be considered when assessing the risk-benefit profile
of peginterferon/ribavirin therapy in children with HCV infection.
In deciding to treat children with chronic HCV, the risks and
benefits should include both the timing of interferon-based therapy,
and the possibility that interferon-free regimens may likely be
available to children in the next 5 to 10 years. Copyright © ESPGHAN and NA
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